Evidence map›Paper›PMID 34365291›Full record

ArticleJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2021

Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma.

Dominique A Garrison, Yan Jin, Muhammad Erfan Uddin, Alex Sparreboom, Sharyn D Baker

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Dominique A GarrisonDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Yan JinDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Muhammad Erfan UddinDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Alex SparreboomDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Sharyn D BakerDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA. Electronic address: baker.2480@osu.edu.
The Ohio State University · US

Funding

Tyrosine kinase inhibitors for the treatment of childhood AMLR01CA138744 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, SHARYN D · 2010 to 2019
$3.3M
NCI NIH HHS R01 CA138744
6 · The paper itself

Abstract

A simple, fast and precise LC-MS/MS method for the quantitation of the tyrosine kinase inhibitor gilteritinib was developed and validated for micro-volumes of mouse plasma. The assay procedure involved a one-step extraction of gilteritinib and the internal standard [

Indexed as

Aniline CompoundsAnimalsChromatography, LiquidFemaleHEK293 CellsHumansLimit of DetectionLinear ModelsMicePyrazinesReproducibility of ResultsTandem Mass SpectrometryAniline CompoundsgilteritinibPyrazinesGilteritinibLC-MS/MSMouse plasmaPharmacokinetics

Identifiers

PMID34365291
PMCPMC8687142
OpenAlexW3187352279

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.